Drugs & Targets FDA approves Tecvayli + Darzalez Faspro for r/r MM as second line treatment March 13, 2026Vol.52 No.10
Drugs & Targets Ipsen voluntarily withdraws Tazverik in follicular lymphoma and epithelioid sarcoma March 13, 2026Vol.52 No.10
Drugs & Targets FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM March 06, 2026Vol.52 No.09
Drugs & Targets FDA grants tentative approval for Lutetium Lu 177 dotatate March 06, 2026Vol.52 No.09
Drugs & Targets Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery March 06, 2026Vol.52 No.09
Drugs & Targets FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer February 27, 2026Vol.52 No.08
Drugs & Targets FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC February 27, 2026Vol.52 No.08
Drugs & Targets FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer February 20, 2026Vol.52 No.07
